All In Biotech

Drug Trial Radar · NCT03255694

A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

A Phase 2 Study Extension Period of Pegylated Somatropin (PEG-somatropin) in the Treatment of Children With Idiopathic Short Stature: An Open, Non-controlled Observational Study.

Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

May 12, 2017

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Sponsor type
Industry
Collaborators
Tongji Hospital; The First Hospital of Jilin University; Affiliated Hospital of Jiangnan University; The First Affiliated Hospital with Nanjing Medical University; Shanghai Children's Hospital; The Children's Hospital of Zhejiang University School of Medicine; Children's Hospital of Fudan University; Jiangxi Province Children's Hospital; Hunan Children's Hospital; Beijing Children's Hospital; Children's Hospital of Soochow University; Wuxi Women's & Children's Hospital
First posted
Aug 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

After the first stage (52 weeks) of Phase II clinical trial, Pegylated recombinant human growth hormone (PEG-rhGH) injection of appropriate dose in compliance with ISS clinical treatment strategy is used to treat children with ISS (Idiopathic Short Stature). The long-term efficacy and safety of the investigational product are evaluated, which can provide more scientific and reliable medication guidance information for clinical diagnosis and treatment.

Conditions

  • Dwarfism

Interventions

  • PEG-somatropinDrug

    After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of yearly height velocity (ΔHV)Time frame: Baseline,the end of 3-year addendum

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Children's Hospital of Fudan University

    Shanghai, China

  • Shanghai Children's Hospital

    Shanghai, China

  • Beijing Children's Hospital, Capital Medical University, National Center for Children's Health

    Beijing, Beijing Municipality, China

  • Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

    Wuhan, Hubei, China

  • Hunan Children's Hospital

    Changsha, Hunan, China

  • Children's Hospital of Soochow University

    Naning, Jiangsu, China

  • The First Affiated Hospital of Nanjing Medical Universit

    Nanjing, Jiangsu, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China

  • Wuxi Children's Hospital

    Wuxi, Jiangsu, China

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Children's Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.